Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Ralph Hauke (NPI 1578511283)

Field	Value
Entity Type	Individual
Organization	Ralph Hauke
Address	7500 Mercy Rd
City	Omaha
State	NE
ZIP	68124
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 5, 2006

Payer Source	Total Paid
Medicare	$2.5M
Medicaid	$0

Key Findings

This clinician is a specialty Hematology & Oncology physician based in OMAHA, NE with an NPI enumerated on 2006-05-05 (~20 years ago), indicating long-tenured Medicare participation and established practice history. The mix of high-volume immunotherapy drug codes and infusion/E/M services is consistent with an outpatient oncology infusion practice that manages systemic cancer therapies and related clinic visits.

Medicare is the sole payer on file for this provider — total Medicare revenue is $2.5M and there is no Medicaid billing on file — making the provider effectively single-payer (Medicare) in the available data and concentrating analytic focus on Medicare utilization and drug administration patterns.

Revenue concentration is high: the top three Medicare codes by revenue account for 88.6% of this provider's total Medicare revenue, signaling extreme dependency on a very small set of services. Two oncology drug codes, J9271 and J9299, alone make up the lion’s share of revenue (J9271 is $1.4M and J9299 is $746K), which aligns with a practice that primarily generates income from high-volume immunotherapy injections rather than ancillary services.

J9271 (pembrolizumab) is a clear volume and revenue outlier for this provider: 32K claims generating $1.4M (55.4% of Medicare revenue) and ranking #101 of 1841 providers nationally (95th percentile). The data characterize the provider as notably above typical national volume for pembrolizumab, suggesting a major focus on PD-1 inhibitor therapy relative to the national peer set.

J9299 (nivolumab) also represents a substantial revenue stream with 31.1K claims and $746K (30.0% of Medicare revenue), ranking #72 of 505 providers nationally (86th percentile). This placement indicates the provider is a high-volume but not extreme outlier for nivolumab compared with the national cohort, reinforcing a business model centered on checkpoint inhibitor administration.

Evaluation and management and infusion codes are present but secondary: 99214 ($78.1K, 3.1% of revenue) and chemotherapy administration codes such as 96413 ($49.3K, 2.0% of revenue) reflect ongoing outpatient clinical management and administration capacity, but together they contribute only a small fraction compared with J9271/J9299. This pattern implies that the practice’s clinical visits and infusion procedure billing are supporting services around a drug-delivery revenue base dominated by high-cost immunotherapies.

Competitive standing across codes is mixed: for office visit code 99214 the provider ranks in the 97th percentile nationally (#15758 of 479517), indicating notably above-typical volume for E/M visits relative to general providers, while for many chemotherapy and lab add-on codes the provider sits in middle-to-upper percentiles (typical or unremarkable volumes). These rank patterns suggest the provider is a prominent oncology infusion center for certain immunotherapies but a more typical performer on ancillary procedural and lab activity.

Several lower-paid supply and anemia/iron-related injection codes appear at scale but contribute modest revenue (for example, J0881 darbepoetin alfa at $30.6K and J1439 ferric carboxymaltose at $21K). Their presence indicates the practice also manages supportive care commonly paired with oncology treatment, but these items are not major revenue drivers compared with the immunotherapy drugs.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

63 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	32,000	$40	$1.4M
J9299	Injection, nivolumab, 1 mg	31,080	$20	$746K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	880	$90	$78.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	530	$90	$49.3K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	15,280	$1	$30.6K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	200	$130	$26.7K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	440	$60	$26.5K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	190	$130	$24.3K
J0897	Injection, denosumab, 1 mg	1,260	$20	$24K
J1439	Injection, ferric carboxymaltose, 1 mg	21,000	$1	$21K

Showing 1–10 of 63

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 63 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Ralph Hauke — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

63 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	30	14,400	$40	$671.6K
J9299	2	10	19,300	$20	$444.5K
J0897	168	200	2,040	$20	$62.7K
J0881	8	10	17,260	$1	$54.5K
J1439	20	30	25,880	$1	$26.4K
J9217	9	50	110	$130	$20.6K
96413	6	80	60	$90	$18.2K
99214	105	3,210	110	$70	$14.9K
J3490	4	30	60	$160	$11.3K
88185	10	10	480	$20	$9.1K

Showing 1–10 of 63

Related Providers

Other providers that share a Tax Identification Number (TIN) with Ralph Hauke, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Unmc Physicians	NE	Multi-Specialty Clinic/Center	$0	$41.1M
Alegent Health Bergan Mercy Health System	NE	Psychiatry Physician	$0	$3.4M
Stefano Tarantolo	NE	Hematology & Oncology Physician	$3.2M	$0
Samuel Mehr	NE	Nuclear Medicine Physician	$2.5M	$0
Gamini Sooriyaarachchi	FL	Medical Oncology Physician	$2.2M	$0
Ryan Ramaekers	NE	Hematology & Oncology Physician	$2.1M	$0
Joel Michalski	NE	Internal Medicine Physician	$2M	$0
Yungpo Su	NE	Hematology & Oncology Physician	$1.9M	$0
Margaret Block	NE	Hematology & Oncology Physician	$1.7M	$0
Lisa Chaiken	CA	Radiation Oncology Physician	$1.6M	$0

Nearby Providers

Other providers in the same ZIP code as Ralph Hauke, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Alegent Health Bergan Mercy Health System	NE	General Acute Care Hospital	$0	$45.8M
Alegent Creighton Clinic	NE	Family Medicine Physician	$0	$43.2M
Childrens Home Healthcare	NE	Home Health Agency	$0	$40M
Maxim Healthcare Services, Inc.	NE	Home Health Agency	$0	$29.7M
Lutheran Family Services Of Ne, Inc	NE	Mental Health Counselor	$0	$5.8M
Epn Of Nebraska LLC	NE	Emergency Medicine Physician	$0	$5.6M
Pediatric Dental Specialists Of Greater Nebraska - Omaha, LLC	NE	Pediatric Dentistry	$0	$2.5M
Osc LLC	NE	Ambulatory Surgical Clinic/Center	$1.3M	$799.9K
Shoptikal LLC	NE	Eyewear Supplier	$0	$1.9M
House Enterprises Inc	NE	Emotionally Disturbed Childrens' Residential Treatment Facility	$0	$1.8M

Ralph Hauke — Billing Profile & Reimbursement Data

Sign up for Ralph Hauke — Billing Profile & Reimbursement Data policy alerts

Ralph Hauke — Billing Profile & Reimbursement Data

Sign up for Ralph Hauke — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References